Skip to main content
Clinical Trials/NCT05822557
NCT05822557
Completed
Not Applicable

A Study Evaluating a Newly Designed Nutritional Tube Feeding Pouch for Bolus Feeding in Adults

Nutricia UK Ltd15 sites in 1 country30 target enrollmentApril 1, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cancer
Sponsor
Nutricia UK Ltd
Enrollment
30
Locations
15
Primary Endpoint
Health and feeding related quality of life
Status
Completed
Last Updated
last year

Overview

Brief Summary

The primary aim of this study is to evaluate the impact of introducing a new enteral tube feed on health and feeding related quality of life. Secondary aims are to assess ease of use, liking, compliance, gastrointestinal tolerance, nutrient intake, anthropometric changes and safety.

Detailed Description

Bolus enteral tube feeding (termed 'bolus feeding') is an increasingly common method of providing nutritional support to home enterally tube fed (HETF) patients, particularly those who are more active and/or require greater flexibility in their feeding regimen. However, current methods of bolus feeding are complex to administer, messy, may be unhygienic, and require and lead to a significant amount of plastic waste. Therefore, there is a clear need for a simpler and optimised way to provide bolus feeds. The aim of this study is to evaluate the impact of introducing a new enteral tube feed on health and feeding related quality of life, ease of use, liking, compliance, gastrointestinal tolerance, nutritional intake, anthropometry and safety. This is a prospective, longitudinal, 28-day intervention study with a 7-day baseline period.

Registry
clinicaltrials.gov
Start Date
April 1, 2023
End Date
January 25, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • ≥16 years of age
  • Using or requiring an enteral tube feed as part of nutritional management plan
  • Using or about to use bolus tube feeding methods at least once daily
  • Expected to receive at least 400 kcal/day from the intervention feed
  • Written or electronic informed consent from patient, or verbally given consent countersigned by a witness for those physically unable to sign.

Exclusion Criteria

  • Parenteral nutrition contributing more than 70% of total energy requirements
  • Patients with major hepatic dysfunction (i.e., decompensated liver disease)
  • Patients with major renal dysfunction \[i.e., requiring filtration or stage 4/5 chronic kidney disease (CKD)\]
  • Patients receiving inpatient care
  • Participation in other clinical intervention studies within 2 weeks of this study
  • Adults lacking mental capacity to consent
  • Allergy to any study product ingredients
  • Investigator concern regarding ability or willingness of patient to comply with the study requirements.

Outcomes

Primary Outcomes

Health and feeding related quality of life

Time Frame: Baseline to end of intervention (Day 35)

At baseline, and at the mid-point and end of the intervention period, health and feeding related quality of life will be assessed by the FACT-EQ questionnaire.

Secondary Outcomes

  • Ease of administration(Baseline to end of intervention (Day 35))
  • Gastrointestinal tolerance(Baseline to end of intervention (Day 35))
  • Liking of feeding method(Baseline to end of intervention (Day 35))
  • Nutrient intake(Baseline to end of intervention (Day 35))
  • Adverse Events(Baseline to end of intervention (Day 35))
  • Compliance(Baseline to end of intervention (Day 35))
  • Body weight (kg)(Baseline to end of intervention (Day 35))

Study Sites (15)

Loading locations...

Similar Trials